GSK announces changes to the Board
30-Jan-2012
- United Kingdom
GlaxoSmithKline plc announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.
The Board has agreed the following succession arrangements in respect of the Committees on which they serve:
- Mr. Tom de Swaan will succeed Sir Crispin Davis as Chairman of the Remuneration Committee with effect from 1 January 2013. Mr de Swaan has been a member of the Remuneration Committee since May 2009.
- Ms. Judy Lewent will succeed Mr. Tom de Swaan as Chair of the Audit & Risk Committee with effect from 1 January 2013. Ms. Lewent has been a member of the Audit & Risk Committee since April 2011. Mr de Swaan will remain a member of the Audit & Risk Committee following Ms Lewent’s appointment.
- Sir Deryck Maughan will succeed Sir Robert Wilson as Senior Independent Non-Executive Director with effect from the closure of GSK’s AGM in 2013.
In addition, Mr. James Murdoch has decided not to stand for re-election to the Board at GSK’s AGM in 2012.ch & Development.
Other news from the department people
